Andrew Tutt

Summary

Affiliation: Institute of Cancer Research
Country: UK

Publications

  1. pmc Risk estimation of distant metastasis in node-negative, estrogen receptor-positive breast cancer patients using an RT-PCR based prognostic expression signature
    Andrew Tutt
    Breakthrough Breast Cancer Research Unit, King s College, London, UK
    BMC Cancer 8:339. 2008
  2. doi Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial
    Andrew Tutt
    Breakthrough Breast Cancer Research Unit, Guy s Hospital Campus, King s College London School of Medicine, London, UK
    Lancet 376:235-44. 2010
  3. pmc Are triple-negative tumours and basal-like breast cancer synonymous?
    Emad A Rakha
    Breast Cancer Res 9:404; author reply 405. 2007
  4. pmc DART: Denoising Algorithm based on Relevance network Topology improves molecular pathway activity inference
    Yan Jiao
    Statistical Genomics Group, Paul O Gorman Building, UCL Cancer Institute, University College London, 72 Huntley Street, London WC1E 6BT, UK
    BMC Bioinformatics 12:403. 2011
  5. doi Can genetic testing guide treatment in breast cancer?
    Andrew Tutt
    Breakthrough Breast Cancer Research Unit, 3rd Floor Bermondsey Wing Guy s Hospital Campus, Kings College London, London, UK
    Eur J Cancer 44:2774-80. 2008
  6. doi Prognosis of metachronous contralateral breast cancer: importance of stage, age and interval time between the two diagnoses
    Voralak Vichapat
    Cancer Epidemiology Group, Division of Cancer Studies, School of Medicine, King s College London, London, UK
    Breast Cancer Res Treat 130:609-18. 2011
  7. ncbi The relationship between the roles of BRCA genes in DNA repair and cancer predisposition
    Andrew Tutt
    The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, UK
    Trends Mol Med 8:571-6. 2002
  8. doi Therapeutic potential of PARP inhibitors for metastatic breast cancer
    Sheeba Irshad
    Breakthrough Breast Cancer Unit Research Oncology, 3rd Floor Bermondsey Wing, Guy s Hospital Campus, Kings College London School of Medicine, London, SE1 9RT, UK
    Expert Rev Anticancer Ther 11:1243-51. 2011
  9. pmc Molecular characterisation of cell line models for triple-negative breast cancers
    Anita Grigoriadis
    Breakthrough Breast Cancer Research Unit, Guy s Hospital, King s Health Partners AHSC, King s College London School of Medicine, London SE1 9RT, UK
    BMC Genomics 13:619. 2012
  10. doi Molecular heterogeneity of triple-negative breast cancer and its clinical implications
    Sheeba Irshad
    Breakthrough Breast Cancer Research Unit, Research Oncology, Kings College London School of Medicine, Kings Health Partners AHSC, London, UK
    Curr Opin Oncol 23:566-77. 2011

Collaborators

Detail Information

Publications11

  1. pmc Risk estimation of distant metastasis in node-negative, estrogen receptor-positive breast cancer patients using an RT-PCR based prognostic expression signature
    Andrew Tutt
    Breakthrough Breast Cancer Research Unit, King s College, London, UK
    BMC Cancer 8:339. 2008
    ....
  2. doi Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial
    Andrew Tutt
    Breakthrough Breast Cancer Research Unit, Guy s Hospital Campus, King s College London School of Medicine, London, UK
    Lancet 376:235-44. 2010
    ..We therefore assessed the efficacy, safety, and tolerability of olaparib alone in women with BRCA1 or BRCA2 mutations and advanced breast cancer...
  3. pmc Are triple-negative tumours and basal-like breast cancer synonymous?
    Emad A Rakha
    Breast Cancer Res 9:404; author reply 405. 2007
  4. pmc DART: Denoising Algorithm based on Relevance network Topology improves molecular pathway activity inference
    Yan Jiao
    Statistical Genomics Group, Paul O Gorman Building, UCL Cancer Institute, University College London, 72 Huntley Street, London WC1E 6BT, UK
    BMC Bioinformatics 12:403. 2011
    ..g protein interaction networks) or more generally with prior knowledge pathway databases. However, it is unclear how best to use the pathway knowledge information in the context of molecular profiles of any given study...
  5. doi Can genetic testing guide treatment in breast cancer?
    Andrew Tutt
    Breakthrough Breast Cancer Research Unit, 3rd Floor Bermondsey Wing Guy s Hospital Campus, Kings College London, London, UK
    Eur J Cancer 44:2774-80. 2008
    ..results of local surgical and radiation therapy, (3) the benefits from adjuvant systemic therapy and finally (4) whether selection or avoidance of particular systemic agents is guided by the presence of a BRCA1 or BRCA2 germline mutation?..
  6. doi Prognosis of metachronous contralateral breast cancer: importance of stage, age and interval time between the two diagnoses
    Voralak Vichapat
    Cancer Epidemiology Group, Division of Cancer Studies, School of Medicine, King s College London, London, UK
    Breast Cancer Res Treat 130:609-18. 2011
    ..The occurrence of CBC implies a new surveillance and therapeutic situation...
  7. ncbi The relationship between the roles of BRCA genes in DNA repair and cancer predisposition
    Andrew Tutt
    The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, UK
    Trends Mol Med 8:571-6. 2002
    ..An improved understanding of the interactions of BRCA1 and BRCA2 with other proteins in large macromolecular complexes is helping to reveal their exact role in DNA repair...
  8. doi Therapeutic potential of PARP inhibitors for metastatic breast cancer
    Sheeba Irshad
    Breakthrough Breast Cancer Unit Research Oncology, 3rd Floor Bermondsey Wing, Guy s Hospital Campus, Kings College London School of Medicine, London, SE1 9RT, UK
    Expert Rev Anticancer Ther 11:1243-51. 2011
    ..This article discusses the current understanding of PARP inhibition as a treatment for metastatic breast cancer, evidence from clinical trials and addresses its future implications...
  9. pmc Molecular characterisation of cell line models for triple-negative breast cancers
    Anita Grigoriadis
    Breakthrough Breast Cancer Research Unit, Guy s Hospital, King s Health Partners AHSC, King s College London School of Medicine, London SE1 9RT, UK
    BMC Genomics 13:619. 2012
    ..Target validation studies for all BC subtypes have largely employed established BC cell lines, which have proven to be effective tools for drug discovery...
  10. doi Molecular heterogeneity of triple-negative breast cancer and its clinical implications
    Sheeba Irshad
    Breakthrough Breast Cancer Research Unit, Research Oncology, Kings College London School of Medicine, Kings Health Partners AHSC, London, UK
    Curr Opin Oncol 23:566-77. 2011
    ..This review focuses on the increasing understanding of the molecular heterogeneity of TNBC subtypes and the therapeutic implications of this subclassification...
  11. doi Tiling path genomic profiling of grade 3 invasive ductal breast cancers
    Rachael Natrajan
    The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, UK
    Clin Cancer Res 15:2711-22. 2009
    ....